Anlotinib combined with chemotherapy showed a 30.8% ORR and 82.7% DCR in advanced STS patients, indicating promising efficacy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results